WALTHAM,
Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio
Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology
company focused on developing biologic therapeutics to restore
immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial
Officer. Mr. Kalowski brings over 20 years of biopharmaceutical
experience with a focus on strategy, raising capital, and financial
operations.
"Lee has been part of the Q32 Bio team over the past five months
as our interim Chief Financial Officer and an invaluable member of
the team driving the execution and closing of our recent
transactions. I am pleased to welcome Lee as a permanent member of
the team, as we transition into a publicly traded company," said
Jodie Morrison, Chief Executive
Officer of Q32 Bio. "Lee is a deeply experienced biopharmaceutical
executive with a proven track record of taking companies public,
raising capital, and overseeing finance and operations at multiple
publicly traded companies."
"I am excited to be joining full-time in my new role during this
transformative time for the Company," said Mr. Kalowski. "Q32 Bio
has the potential to make meaningful strides in the treatment of
autoimmune and inflammatory diseases and I look forward to
continuing to work with the Q32 Bio leadership team as we advance
bempikibart to Phase 2 clinical data in the second half of this
year and ADX-097 to Phase 2 clinical data in the second half of
2025."
Prior to joining Q32 Bio, Mr. Kalowski served as President and
Chief Financial Officer of Bicycle Therapeutics where he led
strategic finance and operations and oversaw the company's
transition to a public clinical-stage biotech company. While at
Bicycle, Mr. Kalowski led the IPO in 2019 and helped raise
$1 Billion in total, including over
$700 Million in private, public and
non-dilutive financings. Prior to Bicycle, Mr. Kalowski was Chief
Financial Officer of Tokai Pharmaceuticals where he helped lead the
company's IPO in 2014. Earlier, Mr. Kalowski served in global
biotechnology equity research as a Senior Analyst at Credit Suisse
covering companies in the biopharmaceutical industry. Mr. Kalowski
received a B.A. in Biology and Economics from Union College and an MBA from The Wharton School of
the University of Pennsylvania. Mr.
Kalowski is currently a board member of Aro Biotherapeutics.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing
biologic therapeutics targeting potent regulators of the innate and
adaptive immune systems to re-balance immunity in autoimmune and
inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7
/ TSLP receptor pathways and complement system, address immune
dysregulation to help patients take back control of their
lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914),
is a fully human anti-IL-7Rα antibody that re-regulates adaptive
immune function for the treatment of autoimmune diseases. It is
being evaluated in two Phase 2 trials for the treatment of atopic
dermatitis and alopecia areata. The IL-7 and TSLP pathways have
been genetically and biologically implicated in driving several T
cell-mediated pathological processes in numerous autoimmune
diseases. Q32 Bio's program for innate immunity, ADX-097, is based
on a novel platform enabling tissue-targeted regulation of the
complement system without long-term systemic blockade – a key
differentiator versus current complement therapeutics. Q32 Bio has
completed a first-in-human, Phase 1 ascending dose clinical study
of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Forward-Looking Statements
This communication contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, including statements regarding expectations surrounding the
potential, safety, efficacy, and regulatory and clinical progress
of Q32 Bio's product candidates, including bempikibart and ADX-097,
and anticipated milestones and timing, among others.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as "may," "will," "should,"
"would," "expect," "anticipate," "plan," "likely," "believe,"
"estimate," "project," "intend," and other similar expressions
among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the ability to integrate our
business with our merger partner successfully and to achieve
anticipated synergies; the possibility that other anticipated
benefits of the merger will not be realized, including without
limitation, anticipated revenues, expenses, earnings and other
financial results, and growth and expansion of our operations, and
the anticipated tax treatment of the merger; our ability to retain,
attract and hire key personnel; potential adverse reactions or
changes to relationships with employees, suppliers or other parties
resulting from the completion of the merger; potential business
uncertainty, including changes to existing business relationships
that could affect our financial performance; the need for
additional funding, which may not be available; failure to identify
additional product candidates and develop or commercialize
marketable products; the early stage of our development efforts;
potential unforeseen events during clinical trials could cause
delays or other adverse consequences; risks relating to the
regulatory approval process; interim, topline and preliminary
data may change as more patient data become available, and are
subject to audit and verification procedures that could result in
material changes in the final data; our product candidates may
cause serious adverse side effects; the inability to maintain our
collaborations, or the failure of these collaborations; our
reliance on third parties, including for the manufacture of
materials for our research programs, preclinical and clinical
studies; failure to obtain U.S. or international marketing
approval; ongoing regulatory obligations; effects of significant
competition; unfavorable pricing regulations, third-party
reimbursement practices or healthcare reform initiatives; product
liability lawsuits; securities class action litigation; the impact
of global pandemics and general economic conditions on our business
and operations, including the our preclinical studies and clinical
trials; the possibility of system failures or security breaches;
risks relating to intellectual property; significant costs incurred
as a result of operating as a public company; and such other
factors as are set forth in Q32 Bio's periodic public filings with
the SEC, including but not limited to those described under the
heading "Risk Factors" in our Form 8-filed on March 27, 2024. Except as required by applicable
law, we undertake no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-appoints-lee-kalowski-as-president--chief-financial-officer-302106436.html
SOURCE Q32 Bio
